Loading...
XETRM12
Market cap323mUSD
Dec 23, Last price  
16.25EUR
1D
3.17%
1Q
-8.45%
Jan 2017
54.10%
IPO
212.50%
Name

M1 Kliniken AG

Chart & Performance

D1W1MN
XETR:M12 chart
P/E
30.25
P/S
0.98
EPS
0.54
Div Yield, %
0.64%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
37.14%
Revenues
316m
+10.88%
6,081,00023,017,00034,926,33435,955,00047,194,52565,208,58677,216,857159,590,839314,610,275285,291,186316,318,613
Net income
10m
+137.98%
109,0004,585,0006,630,7555,007,4605,777,9716,612,5679,729,0306,823,0108,905,0914,317,35410,274,283
CFO
9m
-57.58%
-5,215,000912,575-171,7967,936,0002,085,9642,860,919-3,524,3119,381,13415,658,05521,023,1318,917,096
Dividend
Jul 18, 20240.5 EUR/sh
Earnings
May 21, 2025

Profile

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.
URL
https://www.m1-kliniken.de/
IPO date
Sep 14, 2015
Employees
366
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
316,319
10.88%
285,291
-9.32%
314,610
97.14%
Cost of revenue
290,894
272,554
297,663
Unusual Expense (Income)
NOPBT
25,424
12,737
16,947
NOPBT Margin
8.04%
4.46%
5.39%
Operating Taxes
4,779
3,163
3,544
Tax Rate
18.80%
24.83%
20.91%
NOPAT
20,645
9,574
13,403
Net income
10,274
137.98%
4,317
-51.52%
8,905
30.52%
Dividends
(1,981)
(1,823)
(1,658)
Dividend yield
0.92%
1.10%
1.19%
Proceeds from repurchase of equity
3,949
13,804
4,725
BB yield
-1.84%
-8.32%
-3.39%
Debt
Debt current
2,971
6,219
18,432
Long-term debt
20,493
13,449
12,502
Deferred revenue
10,324
8,127
Other long-term liabilities
11
54
60
Net debt
(231)
(39,834)
(30,189)
Cash flow
Cash from operating activities
8,917
21,023
15,658
CAPEX
(455)
(1,772)
(1,336)
Cash from investing activities
(9,364)
(1,770)
(266)
Cash from financing activities
(14,809)
(21,968)
4,533
FCF
14,149
15,192
36,633
Balance
Cash
22,756
47,499
49,120
Long term investments
939
12,003
12,003
Excess cash
7,879
45,237
45,393
Stockholders' equity
99,734
107,095
101,800
Invested Capital
148,025
114,863
123,587
ROIC
15.71%
8.03%
11.07%
ROCE
16.12%
7.81%
9.90%
EV
Common stock shares outstanding
19,126
18,315
18,580
Price
11.20
23.62%
9.06
20.80%
7.50
-18.83%
Market cap
214,210
29.09%
165,934
19.08%
139,349
-18.85%
EV
243,953
175,532
154,037
EBITDA
30,735
18,600
22,591
EV/EBITDA
7.94
9.44
6.82
Interest
1,347
828
917
Interest/NOPBT
5.30%
6.50%
5.41%